Sigma Healthcare

The Business

Sigma supplies roughly 2,500 pharmacies from 11 distribution centres and owns the franchise systems behind Chemist Warehouse, My Chemist, Amcal and Discount Drug Stores, a network of around 950 stores. It holds an estimated 70%+ share of Australian pharmaceutical wholesale, built on the 2024 reverse merger between the old ASX-listed Sigma and the privately-owned Chemist Warehouse group. Franchisees carry the store-level capital; Sigma earns wholesale margin, franchise fees, supplier rebates and media income, a model closer to a toll collector than a traditional distributor.

Recent Performance

The stock has run from around $0.70 before the merger to $2.62 today, a re-rating built on merger completion and an unexpected demand shock: GLP-1 weight-loss medicines have pushed Chemist Warehouse like-for-like sales to 13.4%, more than double the sector's normal 5-6% pace. Earnings momentum has been strong, with FY26 EBITDA of $1,158 million and $32.6 million of a targeted $100 million merger synergy already banked.

Outlook

We expect revenue growth to decelerate from 12.5% in FY27 to 6.2% by FY30 as the GLP-1 tailwind normalises and store rollout matures. EBITDA margin should peak near 11.5% around FY29 as synergies complete, then fade toward a 10% terminal level as wage inflation and international investment catch up. Synergy capture and roughly 340 further Chemist Warehouse store openings are the visible earnings drivers through the forecast period, with earnings expected to keep growing but at a materially slower rate than the market has become accustomed to over the past two years.

Key Risks

Founders hold 86% of the register, which means only a small fraction of the stock trades freely. Any sell-down of even a modest portion of that stake could compress the scarcity premium currently embedded in the price, a market structure risk rather than a business risk, and one with no company-level fix. Separately, Sigma's wholesale margins are set partly through government policy under the Pharmaceutical Benefits Scheme, and any reform that cuts regulated margins would materially compress group EBIT. A third risk sits inside the current growth story itself: an estimated 3-5 percentage points of the current 13.4% like-for-like growth rate is attributable to GLP-1 medicine demand, and if this normalises toward more typical sector growth rates, revenue growth roughly halves and operating leverage works in reverse.

What to Watch

• February 2027 1H27 results and like-for-like disclosure — the thesis-defining event; a materially lower like-for-like reading would confirm GLP-1 normalisation is underway and would pressure the multiple.
• CY2026 First UK store opening — an early proof point for whether the franchise model exports successfully.
• Ongoing ASX substantial holder notices — any founder sell-down would be the clearest signal the scarcity premium is unwinding.

Company Description

Sigma Healthcare is Australia's largest pharmaceutical wholesaler and the franchisor behind Chemist Warehouse, My Chemist, Amcal and Discount Drug Stores, roughly 950 stores nationally. Wholesale distribution runs through 11 distribution centres servicing around 2,500 pharmacies and generates the bulk of group revenue, supplemented by franchise fees, supplier rebates and media income from the retail network. An international arm covering New Zealand, Ireland and a new UK joint venture adds a further, smaller growth leg. The business is best understood as an integrated distribution and franchise platform rather than a pure wholesaler, which is why its gross margin of around 18% sits well above pure-play distribution peers.

Where the Growth Is

GLP-1 weight-loss medicines have driven Chemist Warehouse like-for-like sales to 13.4%, both directly through script volumes and indirectly through adjacent categories such as vitamins and protein supplements. This is layered on top of $32.6 million of a $100 million merger synergy target already delivered. We expect the like-for-like rate to normalise toward 7-8% as adoption curves flatten, but combined with synergy completion and continued store rollout, this remains the most significant identifiable growth lever in the business over the next few years.

Competitive Position

Pharmacy ownership laws restrict who can own a pharmacy in Australia, and PBS government funding underpins prescription revenue, together forming a regulatory barrier that has kept Sigma's wholesale share above 70% and stable. Replicating the distribution network, which serves 2,500 pharmacies from 11 centres, would cost a new entrant well over $2 billion, a barrier scale alone provides. Franchisees are locked into multi-year agreements covering supply chain, technology and branding, making switching costly and network attrition low. We see this position holding for at least the next seven years, with no credible domestic challenger visible.

Management & Capital Discipline

The Chemist Warehouse founders retain 86% of the company, an alignment level rarely seen at this market capitalisation. Capital allocation has been disciplined: capital expenditure runs at just 0.5% of revenue, reflecting the franchise structure where store-level capital sits with franchisees, while the dividend payout ratio has held in a 55-65% band alongside active deleveraging. One observation worth flagging: management describes GLP-1 demand as an "enduring" structural shift rather than a cyclical wave, a framing that understandably favours optimism about the company's single largest growth driver.

Financial Position

Sigma's balance sheet carries net debt at roughly half a turn of EBITDA, comfortably within covenant and supported by several hundred million dollars of undrawn facilities. Fixed charge cover sits multiples above covenant minimums. Combined with the capital-light franchise model and non-discretionary demand for pharmaceuticals, the company is well placed to absorb a downturn without balance sheet stress, even as working capital has grown faster than sales over the past year.